<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230802</url>
  </required_header>
  <id_info>
    <org_study_id>DK44128 (completed)</org_study_id>
    <nct_id>NCT00230802</nct_id>
  </id_info>
  <brief_title>Thyroid Hormone Dose Adjustment in Pregnancy</brief_title>
  <official_title>Thyroid Hormone Dose Adjustments During Pregnancy in Women With Primary Hypothyroidism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our aim is to compare the safety and efficacy of 2 different empiric levothyroxine dose
      adjustment recommendations to be made at the first confirmation of pregnancy in women with a
      history of hypothyroidism. Subjects will be women with a prior diagnosis of hypothyroidism
      who are taking thyroid hormone replacement and who are less than 8 weeks pregnant. Upon
      confirmation of pregnancy, subjects will be randomized to increase their weekly thyroid
      hormone dose by either 2 or 3 tablets (28 or 42%). Thyroid function will be evaluated every
      two weeks in the first 20 weeks and then again at week 30 and post-partum. Primary endpoints
      will be the proportion of women in each group who remain euthyroid throughout the first
      trimester and throughout pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our aim is to compare the safety and efficacy of 2 different empiric levothyroxine dose
      adjustment recommendations to be made at the first confirmation of pregnancy in women with a
      history of hypothyroidism. Subjects will be women with a prior diagnosis of hypothyroidism
      who are taking thyroid hormone replacement and who are less than 8 weeks pregnant. Upon
      confirmation of pregnancy, subjects will be randomized to increase their weekly thyroid
      hormone dose by either 2 or 3 tablets (28 or 42%). Thyroid function will be evaluated every
      two weeks in the first 20 weeks and then again at week 30 and post-partum. Primary endpoints
      will be the proportion of women in each group who remain euthyroid throughout the first
      trimester and throughout pregnancy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation</measure>
    <time_frame>9 months</time_frame>
    <description>The proportion of patients in each treatment arm euthyroid through gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pregnancy</condition>
  <condition>Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>2 tablet increase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 tablet increase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticipatory dose increase of levothyroxine</intervention_name>
    <description>as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.</description>
    <arm_group_label>2 tablet increase</arm_group_label>
    <arm_group_label>3 tablet increase</arm_group_label>
    <other_name>Levoxyl,</other_name>
    <other_name>Synthroid,</other_name>
    <other_name>Unithroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levothyroxine</intervention_name>
    <description>patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week</description>
    <arm_group_label>2 tablet increase</arm_group_label>
    <other_name>levoxyl,</other_name>
    <other_name>synthroid</other_name>
    <other_name>unithroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levothyroxine</intervention_name>
    <description>patients will increase levothyroxine by 3 extra tablets of their current dose per week.</description>
    <arm_group_label>3 tablet increase</arm_group_label>
    <other_name>Levoxyl,</other_name>
    <other_name>Synthroid,</other_name>
    <other_name>Unithroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with a prior diagnosis of hypothyroidism, currently receiving levothyroxine
             therapy

          -  less than 8 weeks pregnant

        Exclusion Criteria:

          -  cardiac disease, renal failure

          -  not euthyroid biochemically within 6 months pre-pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Alexander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Yassa L, Marqusee E, Fawcett R, Alexander EK. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. J Clin Endocrinol Metab. 2010 Jul;95(7):3234-41. doi: 10.1210/jc.2010-0013. Epub 2010 May 12.</citation>
    <PMID>20463094</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2005</study_first_submitted>
  <study_first_submitted_qc>September 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2005</study_first_posted>
  <results_first_submitted>May 29, 2012</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2016</results_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Erik K. Alexander</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>hypothyroidism</keyword>
  <keyword>levothyroxine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2 Tablet Increase</title>
          <description>Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)</description>
        </group>
        <group group_id="P2">
          <title>3 Tablet Increase</title>
          <description>Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 Tablet Increase</title>
          <description>Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)</description>
        </group>
        <group group_id="B2">
          <title>3 Tablet Increase</title>
          <description>Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="3"/>
                    <measurement group_id="B2" value="28" spread="5"/>
                    <measurement group_id="B3" value="29" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation</title>
        <description>The proportion of patients in each treatment arm euthyroid through gestation</description>
        <time_frame>9 months</time_frame>
        <population>proportion of patients in each treatment arm euthyroid through gestation</population>
        <group_list>
          <group group_id="O1">
            <title>2 Tablet Increase</title>
            <description>Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)</description>
          </group>
          <group group_id="O2">
            <title>3 Tablet Increase</title>
            <description>Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation</title>
          <description>The proportion of patients in each treatment arm euthyroid through gestation</description>
          <population>proportion of patients in each treatment arm euthyroid through gestation</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State</title>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 Tablet Increase</title>
            <description>Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)
Anticipatory dose increase of levothyroxine: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
levothyroxine: patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week</description>
          </group>
          <group group_id="O2">
            <title>3 Tablet Increase</title>
            <description>Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).
Anticipatory dose increase of levothyroxine: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
levothyroxine: patients will increase levothyroxine by 3 extra tablets of their current dose per week.</description>
          </group>
        </group_list>
        <measure>
          <title>the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy.</title>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 Tablet Increase</title>
            <description>Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)
Anticipatory dose increase of levothyroxine: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
levothyroxine: patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week</description>
          </group>
          <group group_id="O2">
            <title>3 Tablet Increase</title>
            <description>Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).
Anticipatory dose increase of levothyroxine: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
levothyroxine: patients will increase levothyroxine by 3 extra tablets of their current dose per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2 Tablet Increase</title>
          <description>Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)</description>
        </group>
        <group group_id="E2">
          <title>3 Tablet Increase</title>
          <description>Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erik Alexander, MD</name_or_title>
      <organization>Brigham &amp; Women's Hospital</organization>
      <phone>6177325666</phone>
      <email>ekalexander@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

